Companies › Sichuan Kelun Pharmaceutical
1 active drug program in 4 registered trials: 1 Phase 1, 1 Phase 4, 1 Phase 3, 1 Phase 2; Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 1 | Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06674694 | Brexpiprazole | Phase 1 | Schizophrenia Disorders | Psychiatry | Jun 2026 |
| NCT04066192 | Brexpiprazole | Phase 2 | Alcohol Use Disorder | Psychiatry | Aug 2026 |
| NCT05017311 | Brexpiprazole | Phase 4 | Major Depressive Disorder | Psychiatry | Dec 2028 |
| NCT04569448 | Brexpiprazole | Phase 3 | Bipolar Depression | Psychiatry | Sep 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.